Business Context and Reporting Period
This Form 8-K was filed by Aptevo Therapeutics Inc. on December 9, 2025. The report discloses a significant clinical development event regarding the Company's lead candidate, mipletamig, presented at the American Society of Hematology (ASH) 2025 annual meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or quantitative financial data.
Material Changes
The material change reported is the announcement of clinical data from the Phase 1b/2 RAINIER trial. Key findings include:
- Indication: Frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy.
- Regimen: Mipletamig combined with azacitidine (AZA) and venetoclax (VEN).
- Results: High remission rates and a compelling safety/tolerability profile observed across dose-optimization Cohorts 1-3.
Guidance, Outlook, and Risks
Management Commentary: The Company characterized the safety and remission data as "compelling," suggesting a positive outlook for the development of mipletamig in the specified patient population.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainties of clinical development. The press release attached as Exhibit 99.1 contains the full details of the announcement.
Investor Verification Checklist
- Verify the specific numerical remission rates and safety data points in the attached press release (Exhibit 99.1).
- Confirm the total number of patients enrolled in Cohorts 1-3 of the RAINIER trial.
- Review the Company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial liquidity data.
- Assess the competitive landscape for AML treatments in the "unfit for intensive chemotherapy" segment.